IVF Industry Trade Group Uses Advocacy Non-Profit to Push Money-Making Agenda
By Editor,
ReproTech Truths
| 04. 10. 2019
In the last few years, ASRM has aggressively courted RESOLVE, once a purely grassroots group of women helping women get support for infertility. RESOLVE’s grassroots nationwide membership was its crown jewel.
Eager to gain access to RESOLVE’s membership, Big Pharma, along with ASRM, have each made large cash infusions in the form of sponsorships and events.

Industry Mouth Piece
RESOLVE has since become a lobbying group for the industry. Its well-compensated executive team gets paid by Coulter Companies, now MCI USA according to RESOLVE’s latest tax filings. The industry-funded team works alongside its corporate council, donors and advocates — a who’s who of IVF clinic owners and service providers — to mobilize consumers to do its bidding: lobby to get insurance companies to compensate the industry for dispensing IVF cycles. It opens up a large untapped revenue stream.
RESOLVE today announced its full embrace of ASRM with an email blast that reads in part:
“ASRM has committed to a three-year investment in RESOLVE’s Access to Care programs, which will allow for new staff resources to grow these important programs...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Hannah Devlin, The Guardian | 07.05.2025
Scientists are just a few years from creating viable human sex cells in the lab, according to an internationally renowned pioneer of the field, who says the advance could open up biology-defying possibilities for reproduction.
Speaking to the Guardian, Prof...